Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men

Heart

Volumn 81, Issue 1, 1999, Pages 40-46

  Haq, I U ^a   Ramsay, L E ^a,b   Yeo, W W ^a   Jackson, P R ^a   Wallis, E J ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Ischaemic heart disease; Prevention; Risk factors

Indexed keywords

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; CORRELATION FUNCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RISK FACTOR; UNITED KINGDOM;

EID: 0032996943     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.81.1.40     Document Type: Article

References (35)

1. 1 Pyörälä K, De Backer G, Graham I, et al on behalf of the Task Force. Prevention of coronary heart disease in clinical practise. Recommendations of the task force of the European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994;15:1300-31.
2. 2 Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand. 1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. NZ Med J 1996;109:224-32.
3. 3 Haq IU, Jackson PR, Yeo WW, et al. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995;346:1467-71.
4. 4 Ramsay LE, Haq IU, Jackson PR, et al. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet 1996;348: 387-8.
5. 5 Ramsay LE, Haq IU, Jackson PR, et al. The Sheffield table for primary prevention of coronary heart disease: corrected. Lancet 1996;348:1251-2.
6. 6 Jackson R, Barham P, Bills J, et al. Management of raised blood pressure in New Zealand: a discussion document. BMJ 1993;307:107-10.
7. 7 Guidelines for the management of mildly raised blood pressure in New Zealand. Wellington: Core Services Committee, Ministry of Health; 1995.
8. 8 Grover SA, Coupal L, Hu X-P. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? JAMA 1995;274:801-6.
9. 9 Ramsay LE, Haq IU, Yeo WW, et al. Interpretation of prospective trial in hypertension: do treatment guidelines accurately reflect current evidence? J Hypertens 1996; 14(suppl 5):S187-94.
10. 10 Anderson KM, Odell PM, Wilson PWF, et al. Cardiovascular disease risk profiles. Am Heart J 1991;121:293-8.
11. 11 Keys A, Aravanis C, Blackburn H, et al. Probability of middle-aged men developing coronary heart disease in five years. Circulation 1972;45:815-28.
12. 12 Leaverton PE, Sorlie PD, Kleinman JC, et al. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J Chron Dis 1987;40:775-84.
13. 13 Robson J. Information needed to decide about cardiovascular treatment in primary care. BMJ 1997;314:277-80.
14. 14 Chambless LE, Dobson AJ, Patterson CC, et al. On the use of a logistic risk score in predicting risk of coronary heart disease. Statistics in Medicine 1990;9:385-96.
15. 15 Brand RJ, Rosenman RH, Sholtz RI, et al. Multivariate prediction of coronary heart disease in the Western collaborative group study compared to the findings of the Framingham study. Circulation 1976;53:348-55.
16. 16 The Pooling Project Research Group. Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. J Chron Dis 1978;31:201-306.
17. 17 Laurier D, Phong Chau N, Cazelles B, et al and the PCV-METRA Group. Estimation of CHD risk in a French working population using a modified Framingham model. J Clin Epidemiol 1994;47:1353-64.
18. 18 Gordon T, Garcia-Palmieri MR, Kagan A, et al. Differences in coronary heart disease in Framingham, Honolulu and Puerto Rico. J Chron Dis 1974;27:329-44.
19. 19 Keys A, Menotti A, Aravanis C, et al. The Seven Countries study: 2289 deaths in 15 years. Preventive Medicine 1984;13:141-54.
20. 20 Schulte H, Assmann G. CHD risk equations, obtained from the Framinghan heart study, applied to the PROCAM study. Cardiovascular Risk Factors 1991;1:126-33.
21. 21 West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland coronary prevention study. Am J Cardiol 1997;79:756-62.
22. 22 SBU The Swedish Council on Technology Assessment in Health Care. Moderately elevated blood pressure. J Intern Med 1995;238(suppl):737.
23. 23 Assman G. Lipid metabolism disorders and coronary heart disease. München: MMV-Medizin-Verl, 1993.
24. 24 The Dundee coronary risk-disk for management of change in risk factors. BMJ 1991;303:744-7.
25. 25 Shaper AG, Pocock SJ, Phillips AN, et al. Identifying men at high risk of heart attacks: strategy for use in general practice. BMJ 1986;293:474-80.
26. 26 Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;i:307-10.
27. 27 Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med 1995;333:1301-7.
28. 28 Haq IU, Ramsay LE, Pickin DM, et al. Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci 1996;91:399-413.
29. 29 Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ 1995;310: 452-4.
30. 30 Johannsen M. Cost-effectiveness of hypertension treatment in Sweden. PharmacoEconomics 1995;7:242-50.
31. 31 Pickin DM, Payne JN, Haq IU, et al. HMG CoA reductase inhibitor treatment in the prevention of coronary heart disease. Trent Institute for Health Services Research. Working Group on Acute Purchasing. Guidance notes for purchasers 96/04.
32. 32 Grover SA, Lowensteyn I, Esrey KL, et al. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ 1995; 310:975-8.
33. 33 Rose G, Tunstall-Pedhoe H, Heller RF. UK heart disease prevention project: incidence and mortality results. Lancet 1983;i:1062-5.
34. 34 Jarrett RJ, Shipley MJ, Rose G. Weight and mortality in the Whitehall study. BMJ 1982;285:535-7.
35. 35 Thompson SG, Pyke SDM, Wood DA. Using a coronary risk score for screening and intervention in general practice. Journal of Cardiovascular Risk 1996;3:301-6.